Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension

William B. White, Thomas W. Littlejohn, Claudio R. Majul, Willie Oigman, Rafael Olvera, Mary Seeber, Helmut Schumacher, Giuseppe Mancia

Research output: Contribution to journalArticle

Abstract

Background: Evaluation of combination therapy with antihypertensive agents by clinic blood pressure (BP) measurements may yield results that differ from out-of-office BP readings. This is of clinical relevance because out-of-office BP values are of prognostic importance. We studied the effects of combining telmisartan and amlodipine on ambulatory BP in patients with stages 1-2 hypertension. METHODS: We conducted an 8-week, placebo-controlled, double-blind, 4×4 factorial design trial in which 562 patients with clinic diastolic BP at least 95 and 119mmHg or less were randomized to receive telmisartan (0, 20, 40, or 80mg) and/or amlodipine (0, 2.5, 5, or 10mg). Ambulatory BP monitoring was performed at baseline and after 8 weeks of treatment; the end points of interest were the changes from baseline in 24-h systolic and diastolic BP. Secondary end points included the proportion of responders (≥10mmHg BP reduction from baseline and/or

Original languageEnglish
Pages (from-to)205-212
Number of pages8
JournalBlood Pressure Monitoring
Volume15
Issue number4
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Blood Pressure
Hypertension
telmisartan amlodipine combination
Amlodipine
Ambulatory Blood Pressure Monitoring
Antihypertensive Agents
Reading
Placebos
Therapeutics

Keywords

  • ambulatory blood pressure monitoring
  • amlodipine
  • factorial design trial
  • telmisartan

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Assessment and Diagnosis
  • Advanced and Specialised Nursing
  • Medicine(all)

Cite this

White, W. B., Littlejohn, T. W., Majul, C. R., Oigman, W., Olvera, R., Seeber, M., ... Mancia, G. (2010). Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Pressure Monitoring, 15(4), 205-212. https://doi.org/10.1097/MBP.0b013e32833c5722

Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. / White, William B.; Littlejohn, Thomas W.; Majul, Claudio R.; Oigman, Willie; Olvera, Rafael; Seeber, Mary; Schumacher, Helmut; Mancia, Giuseppe.

In: Blood Pressure Monitoring, Vol. 15, No. 4, 08.2010, p. 205-212.

Research output: Contribution to journalArticle

White, WB, Littlejohn, TW, Majul, CR, Oigman, W, Olvera, R, Seeber, M, Schumacher, H & Mancia, G 2010, 'Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension', Blood Pressure Monitoring, vol. 15, no. 4, pp. 205-212. https://doi.org/10.1097/MBP.0b013e32833c5722
White, William B. ; Littlejohn, Thomas W. ; Majul, Claudio R. ; Oigman, Willie ; Olvera, Rafael ; Seeber, Mary ; Schumacher, Helmut ; Mancia, Giuseppe. / Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. In: Blood Pressure Monitoring. 2010 ; Vol. 15, No. 4. pp. 205-212.
@article{10a7bfb6db51420c8276ace8f5c1862d,
title = "Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension",
abstract = "Background: Evaluation of combination therapy with antihypertensive agents by clinic blood pressure (BP) measurements may yield results that differ from out-of-office BP readings. This is of clinical relevance because out-of-office BP values are of prognostic importance. We studied the effects of combining telmisartan and amlodipine on ambulatory BP in patients with stages 1-2 hypertension. METHODS: We conducted an 8-week, placebo-controlled, double-blind, 4×4 factorial design trial in which 562 patients with clinic diastolic BP at least 95 and 119mmHg or less were randomized to receive telmisartan (0, 20, 40, or 80mg) and/or amlodipine (0, 2.5, 5, or 10mg). Ambulatory BP monitoring was performed at baseline and after 8 weeks of treatment; the end points of interest were the changes from baseline in 24-h systolic and diastolic BP. Secondary end points included the proportion of responders (≥10mmHg BP reduction from baseline and/or",
keywords = "ambulatory blood pressure monitoring, amlodipine, factorial design trial, telmisartan",
author = "White, {William B.} and Littlejohn, {Thomas W.} and Majul, {Claudio R.} and Willie Oigman and Rafael Olvera and Mary Seeber and Helmut Schumacher and Giuseppe Mancia",
year = "2010",
month = "8",
doi = "10.1097/MBP.0b013e32833c5722",
language = "English",
volume = "15",
pages = "205--212",
journal = "Blood Pressure Monitoring",
issn = "1359-5237",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension

AU - White, William B.

AU - Littlejohn, Thomas W.

AU - Majul, Claudio R.

AU - Oigman, Willie

AU - Olvera, Rafael

AU - Seeber, Mary

AU - Schumacher, Helmut

AU - Mancia, Giuseppe

PY - 2010/8

Y1 - 2010/8

N2 - Background: Evaluation of combination therapy with antihypertensive agents by clinic blood pressure (BP) measurements may yield results that differ from out-of-office BP readings. This is of clinical relevance because out-of-office BP values are of prognostic importance. We studied the effects of combining telmisartan and amlodipine on ambulatory BP in patients with stages 1-2 hypertension. METHODS: We conducted an 8-week, placebo-controlled, double-blind, 4×4 factorial design trial in which 562 patients with clinic diastolic BP at least 95 and 119mmHg or less were randomized to receive telmisartan (0, 20, 40, or 80mg) and/or amlodipine (0, 2.5, 5, or 10mg). Ambulatory BP monitoring was performed at baseline and after 8 weeks of treatment; the end points of interest were the changes from baseline in 24-h systolic and diastolic BP. Secondary end points included the proportion of responders (≥10mmHg BP reduction from baseline and/or

AB - Background: Evaluation of combination therapy with antihypertensive agents by clinic blood pressure (BP) measurements may yield results that differ from out-of-office BP readings. This is of clinical relevance because out-of-office BP values are of prognostic importance. We studied the effects of combining telmisartan and amlodipine on ambulatory BP in patients with stages 1-2 hypertension. METHODS: We conducted an 8-week, placebo-controlled, double-blind, 4×4 factorial design trial in which 562 patients with clinic diastolic BP at least 95 and 119mmHg or less were randomized to receive telmisartan (0, 20, 40, or 80mg) and/or amlodipine (0, 2.5, 5, or 10mg). Ambulatory BP monitoring was performed at baseline and after 8 weeks of treatment; the end points of interest were the changes from baseline in 24-h systolic and diastolic BP. Secondary end points included the proportion of responders (≥10mmHg BP reduction from baseline and/or

KW - ambulatory blood pressure monitoring

KW - amlodipine

KW - factorial design trial

KW - telmisartan

UR - http://www.scopus.com/inward/record.url?scp=77954957139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954957139&partnerID=8YFLogxK

U2 - 10.1097/MBP.0b013e32833c5722

DO - 10.1097/MBP.0b013e32833c5722

M3 - Article

C2 - 20613496

AN - SCOPUS:77954957139

VL - 15

SP - 205

EP - 212

JO - Blood Pressure Monitoring

JF - Blood Pressure Monitoring

SN - 1359-5237

IS - 4

ER -